CN112316155A - 高原儿茶酸负载香菇菌多糖复合物及其制备方法和应用 - Google Patents
高原儿茶酸负载香菇菌多糖复合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN112316155A CN112316155A CN202011241931.2A CN202011241931A CN112316155A CN 112316155 A CN112316155 A CN 112316155A CN 202011241931 A CN202011241931 A CN 202011241931A CN 112316155 A CN112316155 A CN 112316155A
- Authority
- CN
- China
- Prior art keywords
- plateau
- catechin
- lentinan
- loaded
- complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 title claims abstract description 89
- 235000005487 catechin Nutrition 0.000 title claims abstract description 89
- 229950001002 cianidanol Drugs 0.000 title claims abstract description 84
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 title claims abstract description 83
- 229920001491 Lentinan Polymers 0.000 title claims abstract description 74
- 229940115286 lentinan Drugs 0.000 title claims abstract description 74
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 238000010668 complexation reaction Methods 0.000 title description 2
- 239000000843 powder Substances 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 3
- 238000000855 fermentation Methods 0.000 claims description 25
- 230000004151 fermentation Effects 0.000 claims description 23
- 239000000047 product Substances 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 18
- 244000269722 Thea sinensis Species 0.000 claims description 16
- 229920001282 polysaccharide Polymers 0.000 claims description 14
- 239000005017 polysaccharide Substances 0.000 claims description 14
- 240000000599 Lentinula edodes Species 0.000 claims description 13
- 235000013616 tea Nutrition 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 12
- 150000004676 glycans Chemical class 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 12
- 230000035755 proliferation Effects 0.000 claims description 11
- 206010061218 Inflammation Diseases 0.000 claims description 10
- 239000008367 deionised water Substances 0.000 claims description 10
- 229910021641 deionized water Inorganic materials 0.000 claims description 10
- 230000004054 inflammatory process Effects 0.000 claims description 10
- 238000003786 synthesis reaction Methods 0.000 claims description 10
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 9
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 210000002950 fibroblast Anatomy 0.000 claims description 8
- 239000001963 growth medium Substances 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 7
- 230000001737 promoting effect Effects 0.000 claims description 6
- 238000000502 dialysis Methods 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000000835 fiber Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000006210 lotion Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 239000001888 Peptone Substances 0.000 claims description 3
- 108010080698 Peptones Proteins 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 235000009569 green tea Nutrition 0.000 claims description 3
- 235000019319 peptone Nutrition 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 229960004793 sucrose Drugs 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 2
- 125000000129 anionic group Chemical group 0.000 claims description 2
- 239000012295 chemical reaction liquid Substances 0.000 claims description 2
- 239000012043 crude product Substances 0.000 claims description 2
- 239000006185 dispersion Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 2
- 239000007764 o/w emulsion Substances 0.000 claims description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000007762 w/o emulsion Substances 0.000 claims description 2
- 238000003809 water extraction Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 1
- 150000001765 catechin Chemical class 0.000 abstract description 9
- 239000002537 cosmetic Substances 0.000 abstract description 5
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 28
- 239000002158 endotoxin Substances 0.000 description 17
- 229920006008 lipopolysaccharide Polymers 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 15
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 14
- 229960000890 hydrocortisone Drugs 0.000 description 14
- 238000005481 NMR spectroscopy Methods 0.000 description 13
- 238000001514 detection method Methods 0.000 description 10
- 230000006872 improvement Effects 0.000 description 10
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 9
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 9
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 9
- 229940036350 bisabolol Drugs 0.000 description 9
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 9
- 235000001715 Lentinula edodes Nutrition 0.000 description 8
- 230000008961 swelling Effects 0.000 description 8
- 210000003371 toe Anatomy 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- CFFZDZCDUFSOFZ-UHFFFAOYSA-N 3,4-Dihydroxy-phenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C(O)=C1 CFFZDZCDUFSOFZ-UHFFFAOYSA-N 0.000 description 6
- 241000243251 Hydra Species 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000005311 nuclear magnetism Effects 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 210000000707 wrist Anatomy 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- -1 polysaccharide compound Chemical class 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000036572 transepidermal water loss Effects 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于生物化学技术领域,具体涉及一种高原儿茶酸负载香菇菌多糖复合物及其制备方法和应用。高原儿茶酸负载香菇菌多糖复合物干燥状态下为淡灰色粉末,所述复合物由如下重量百分比的原料合成,香菇菌多糖,含量80‑99%;高原儿茶酸,含量1%‑20%;本发明所述的高原儿茶酸负载香菇多糖复合物,可以使高原儿茶酸在化妆品中保证自身稳定的前提下,温和高效发挥作用;本发明的高原儿茶酸负载香菇菌多糖复合物制备过程,可以使得高原儿茶酸的稳定性得到很大提高,而且在化妆品中实现缓慢释放。
Description
技术领域
本发明属于生物化学技术领域,具体涉及一种高原儿茶酸负载香菇菌多糖复合物,还涉及其制备方法及应用。
背景技术
香菇菌多糖,它既是水溶性的,又是电中性的,因此更加适合于化妆品的应用,其拥有优异的抗衰老功效,能够抚平细小皱纹,改善皮肤纹理度。赋予了产品良好的透皮吸收性能,可作为活性成份的释放载体,给予皮肤如丝绸般滋润光滑的触感。
高原儿茶酸,又称3,4-二羟基苯乙酸,在植物中以游离或聚合的形式存在,是酚酸类主要成分之一。它还是重要的生化检测试剂,在生物化学方面的研究和应用一直非常活跃。具有此结构的化合物显示出较多的生理活性,如抗氧化、抗菌、抗病毒、保肝、治疗中枢神经性疾病、抑制环氧酶及酯氧酶的活性等。
痤疮等皮肤问题可由炎症引起,通过抑制炎症并改善皮肤状态可有效改善痤疮、皮肤衰老等问题。在护肤产品中,往往需要搭配多种来产生协同作用起到抑制炎症同时改善皮肤。
发明内容
本发明解决的技术问题至少是提供一种新型高原儿茶酸负载香菇菌多糖复合物及其制备方法和应用,其目的在于融合香菇菌多糖和高原儿茶酸,使二者协同作用用于护肤产品及药物的研发;还提供一种高原儿茶酸负载香菇菌多糖复合物为活性成分的药物。
为实现上述目的,本发明采用如下技术方案,本发明高原儿茶酸负载香菇菌多糖复合物,在干燥状态下为淡灰色粉末状,其结构式如下:
其中,n≥3。
进一步地,所述的高原儿茶酸负载香菇菌多糖复合物由如下重量百分比的原料合成,香菇菌多糖,含量80-99%;高原儿茶酸,含量1%-20%。
一种上述的高原儿茶酸负载香菇菌多糖复合物的制备方法,采用生物发酵提取方法,具体包括以下步骤:
以新鲜绿茶茶叶为主,蔗糖、蛋白胨、磷酸氢钾等为辅,按照茶叶与水重量比为1:1的比例使茶叶和水充分混匀;在121℃高温条件下充分灭菌20-30分钟后得到茶叶培养基;将所述茶叶培养基与香菇菌丝体共培养;对香菇菌丝体的发酵产物水提醇沉分离提取,最终精制得到高原儿茶酸香菇菌多糖复合物。
进一步的,所述香菇菌的品种不限于某单一品种的香菇菌。
一种上述的高原儿茶酸负载香菇菌多糖复合物的制备方法,采用化学合成方法,具体包括以下步骤:
高原儿茶酸与香菇菌多糖以相应的比例混合在去离子水中;加入与高原儿茶酸等当量的DCC(二环己基碳二亚胺)作为缩合剂;在室温下搅拌反应24h;透析24小时,除去多余DCC以及未反应的高原儿茶酸;冷冻干燥,最终得到相应的香菇菌多糖复合物。
上述两种制备方法得到香菇菌多糖复合物为相同产物,干燥状态下均为淡灰色粉末。
进一步的,主要以水性糊剂或凝胶或液体的形式,例如水性液体的形式。
一种高原儿茶酸负载香菇菌多糖复合物的应用,将高原儿茶酸负载香菇菌多糖复合物配制为含水洗液、油包水或水包油乳液、油或油.醇洗液、阴离子或非离子两亲脂质的囊状分散体、含水凝胶、水.醇凝胶、醇凝胶或油.醇凝胶、固体棒或气溶胶。
一种高原儿茶酸负载香菇菌多糖复合物的应用,将高原儿茶酸负载香菇菌多糖复合物用于抗炎、促成纤维细胞增殖、护肤的制剂。
进一步的,所述剂型为临床上可接受的任一剂型。
进一步的,所述高原儿茶酸负载香菇菌多糖复合物为所述抗炎、促成纤维细胞增殖或护肤的唯一活性成分,或该复合物与其他物质一起制备所述抗炎、促成纤维细胞增殖或护肤的制剂。
本发明所述的高原儿茶酸负载香菇多糖复合物,可以使高原儿茶酸在化妆品中保证自身稳定的前提下,温和高效发挥作用;本发明的高原儿茶酸负载香菇菌多糖复合物制备过程,可以使得高原儿茶酸的稳定性得到很大提高,而且在化妆品中实现缓慢释放。
附图说明
图1是单一香菇菌多糖的H1-NMR图;
图2是化学合成制备方法所述的高原儿茶酸负载香菇菌多糖复合物的H1-NMR图;
图3是化学合成制备方法所述的高原儿茶酸负载香菇菌多糖复合物的C13-NMR图;
图4是生物发酵提取方法所述的高原儿茶酸负载香菇菌多糖复合物的H1-NMR图;
图5是生物发酵提取方法所述的高原儿茶酸负载香菇菌多糖复合物的C13-NMR图;
图6是DT001-A和DT001-B分别对炎症因子TNF-α和IL-1β的影响,DT001-A:化学合成的高原儿茶酸负载香菇菌多糖复合物;DT001-B:生物发酵得到的高原儿茶酸负载香菇菌多糖复合物;LPS:脂多糖;GK2:甘草酸二钾;Drag:红没药醇;Hydr:氢化可的松(n=3,**P<0.01);
图7是DT001-A和DT001-B分别对小鼠足趾肿胀的影响,DT001-A:化学合成的高原儿茶酸负载香菇菌多糖复合物;DT001-B:生物发酵得到的高原儿茶酸负载香菇菌多糖复合物;LPS:脂多糖;GK2:甘草酸二钾;Drag:红没药醇;Hydr:氢化可的松(n=3,**P<0.01);
图8是DT001-A和DT001-B分别对成纤维细胞增殖影响的检测,DT001-A:化学合成的高原儿茶酸负载香菇菌多糖复合物;DT001-B:生物发酵得到的高原儿茶酸负载香菇菌多糖复合物;LPS:脂多糖;GK2:甘草酸二钾;Drag:红没药醇;Hydr:氢化可的松(n=3,**P<0.01)。
具体实施方式
下面将结合具体的实施方案对本发明进行进一步的解释,但并不局限本发明。
下述实施例中,如无特殊说明,所用方法为常规方法,所用试剂都来源于市售商品。
实施例1,采用化学合成法制备高原儿茶酸负载香菇菌多糖复合物
称取10克高原儿茶酸(93.6mmol)与100克香菇菌多糖溶于500ml去离子水中,机械搅拌(800转/分钟)10分钟使得高原儿茶酸较好的分散于水溶液中,此时溶液为灰色乳浊液;随后加入19.3克DCC(二环己基碳二亚胺,93.6mmol)作为缩合剂,在室温25℃下继续搅拌24h;反应结束后,反应液体系变得较为透明,为淡灰色溶液;用10KD的透析袋在去离子水中透析3次,每次透析8小时,将透析出的水溶液进行浓缩提取,得到4.7克的高原儿茶酸,因此可以得知有5.3克的高原儿茶酸负载到香菇多糖中;将透析后的反应液进行冷冻干燥,得到105.3克的淡灰色粉末,为高原儿茶酸负载香菇菌多糖复合物。
为鉴定高原儿茶酸是否负载到香菇菌多糖上,本发明采用核磁鉴定的方法,由于该产物为复合物,并非单一结构的纯化合物,因此采用核磁比对的方法,将香菇菌多糖和负载后的产物核磁进行对比,观察是否多出了高原儿茶酸的峰。
详见图1—单一香菇菌多糖的H1-NMR和图2—化学合成制备的DT001的H-NMR;
由图1和图2对比单一香菇菌多糖及负载后的产物(即高原儿茶酸负载香菇菌多糖复合物)的氢谱,我们可以直观且明确地发现化学位移6.6-6.8出现了明显的高原儿茶酸苯环上的峰,而这些峰是香菇菌多糖和DCC均不可能出现的峰。
为了进一步验证高原儿茶酸已经负载到香菇菌多糖上,还进行了C13-NMR验证,详见图3—化学合成制备而得的产物(即高原儿茶酸负载香菇菌多糖复合物)的C13-NMR,通过单一香菇菌多糖和负载后产物的核磁谱图,可以推断出高原儿茶酸已经负载到香菇菌多糖上,而根据透析出的高原儿茶酸的数量,可以推算此反应得到的产物为5%高原儿茶酸负载的香菇菌多糖(记为DT001-A)。
实施例2,采用生物发酵提取法制备高原儿茶酸负载香菇菌多糖复合物
称取1公斤新鲜绿茶茶叶,同时加入40g蔗糖、6g蛋白胨、6g磷酸二氢钾等,然后按照茶叶与水重量比为1:1的比例使茶叶和水充分混匀;在121℃高温条件下充分灭菌20-30分钟后得到茶叶培养基;待培养基冷却至室温后,在超净工作台中将100克香菇菌丝体加入到1kg所述茶叶培养基中,于28℃,130rpm摇床里培养30d后,收集菌丝体和发酵液并对香菇菌丝体的发酵产物水提醇沉分离提取,得到复合物粗品;将粗品复溶于500ml去离子水中得到灰色溶液,用10KD的透析袋在去离子水中透析3次,每次透析8小时,将透析后的反应液进行冷冻干燥,得到13.2克的淡灰色粉末,为负载后的高原儿茶酸负载香菇菌多糖复合物。
为鉴定茶叶中的高原儿茶酸是否负载到香菇菌多糖上,采用核磁鉴定的方法。由于实施例1中已经验证了高原儿茶酸负载后在H1-NMR中峰的位置,因此只需要在相同的化学位移有相同且等比例的峰,即可确认发酵法得到的也为高原儿茶酸负载的香菇菌多糖复合物。
详见图4—生物发酵提取制备的DT001的H1-NMR;通过对比生物发酵提取法和化学合成法得到的所述复合物的H1-NMR,即图4和图2对比后,可以发现生物发酵提取法得到的复合物在化学位移6.6-6.8出现了明显的高原儿茶酸的峰。且通过对比相应峰的积分,合成法制备复合物6.8左右峰的积分为0.36,而发酵法6.8左右峰的积分为0.30,在同一区间内,由于化学合成法制备复合物负载的高原儿茶酸为5%,因此推算发酵法得到复合物的高原儿茶酸负载为4%(记为DT001-B)。
为了进一步验证高原儿茶酸已经负载到香菇菌多糖上,还进行了C13-NMR验证,详见图5—生物发酵提取制备而得的产物(即高原儿茶酸负载香菇菌多糖复合物)的C13-NMR,通过单一香菇菌多糖和负载后产物的核磁谱图,可以推断出高原儿茶酸已经负载到香菇菌多糖上,而根据透析出的高原儿茶酸的数量,可以推算此反应得到的产物为4%高原儿茶酸负载的香菇菌多糖(记为DT001-B)。
另外,通过图4和图5的直观对比,可进一步验证采用化学合成方法和生物发酵提取方法分别制得的高原儿茶酸负载香菇菌多糖复合物为相同产物(记为DT001)。
下面给出高原儿茶酸负载香菇菌多糖复合物的生物活性方面的应用实例。
实施例3.高原儿茶酸负载香菇菌多糖复合物对炎症因子TNF-α和IL-1β的影响检测
检测方法:
小鼠巨噬细胞RAW264.7接种于12孔板内,37℃,5%CO2培养箱培养24h后,加入40mg/L脂多糖(LPS)作用4h诱导炎症反应,适当浓度的DT001-A、DT001-B、GK2和Hydr于LPS加入前2h加入。LPS作用4h后,收集细胞上清,按照ELISA试剂盒说明书测定TNF-α和IL-1β的含量。
结果详见图6—DT001对炎症因子TNF-α和IL-1β的影响;其中,DT001-A:化学合成的高原儿茶酸负载香菇菌多糖复合物;DT001-B:生物发酵得到的高原儿茶酸负载香菇菌多糖复合物;LPS:脂多糖;GK2:甘草酸二钾;Hydr:氢化可的松。
结论:
无论是化学合成的DT001还是通过生物发酵法得到的DT001,均可以显著抑制LPS诱导引起的炎症因子TNF-α和IL-1β含量的上升,且效果显著优于阳性药甘草酸二钾和糖皮质激素氢化可的松。
实施例4.对小鼠足趾肿胀的影响检测
检测方法:
1%羧甲基纤维素钠配药,使成凝胶状,并在每鼠右下足趾正反两面均匀涂抹药物。半小时后,每鼠左右两足趾均皮下注射1%角叉菜胶约0.025mL,空白对照组小鼠不做处理。5h后脱颈处死,沿踝关节减下左右两足,称重,计算肿胀度及肿胀率,并做统计分析。
肿胀度=炎症组足趾重量-空白组足趾重量
结果详见图7—DT001-A和DT001-B分别对小鼠足趾肿胀的影响,DT001-A:化学合成的高原儿茶酸负载香菇菌多糖复合物;DT001-B:生物发酵得到的高原儿茶酸负载香菇菌多糖复合物;LPS:脂多糖;GK2:甘草酸二钾;Drag:红没药醇;Hydr:氢化可的松(n=3,**P<0.01);
结论:
化学合成的DT001和通过生物发酵法得到的DT001均可以显著抑制角叉菜胶对小鼠足趾造成的肿胀,且效果显著优于阳性药甘草酸二钾和糖皮质激素氢化可的松。
实施例5.DT001对成纤维细胞增殖影响的检测
护肤品对抗炎的治疗过程中还涉及皮肤损伤处的修复,而成纤维细胞的增殖是主要的表现形式。本部分实验检测DT001及阳性药物甘草酸二钾(GK2)和氢化可的松(Hydr)对成纤维细胞NIH-3T3的增殖影响。实验方法及结果如下:
检测方法:
小鼠成纤维细胞NIH-3T3以5000cells/孔密度接种于96孔板内,37℃,5%CO2培养箱培养12h左右待细胞贴壁,适当浓度的DT001、GK2和Hydr加入到对应孔内,同时设一组空白对照,每组5个重复。继续培养48h后,每空加25μL MTT并继续孵育4h。随后DMSO溶解甲瓒并用酶标仪检测OD490吸光值,对数据做统计分析。
结果详见图8—DT001-A:化学合成的高原儿茶酸负载香菇菌多糖复合物;DT001-B:生物发酵得到的高原儿茶酸负载香菇菌多糖复合物;LPS:脂多糖;GK2:甘草酸二钾;Hydr:氢化可的松。(n=3,*P<0.05);
结论:
化学合成的DT001和通过生物发酵法得到的DT001均可以显著促进成纤维细胞增殖,且两种途径得到的DT001效果相当。
实施例6.DT001对皮肤改善情况的检测
检测方法:
招募30名志愿者(其中15男,15女),随机分为5组(对照、DT001、GK2、Drag、Hydr),其中每组男女各3人。每次使用时先用湿巾或水洗将右手手腕内侧清理干净,随后护肤品均匀擦拭于右手手腕内侧部位,每天早晚各一次,连续使用4周共28天。分别于第0、7、14、28天使用DermaLab仪器检测TEWL(经表皮水流失)、Ultrasound(超声)、Elasticity(弹性)和Skin Color(肤色)共四项指标,每次检测时志愿者右手手腕内侧湿巾擦拭干净并晾晒20分钟左右至晾干后开始检测。仪器所在房间不通风,无阳光直射,室温保持在24-25℃,湿度保持在40%。最后对得到的数据做统计分析。
结果:
表1.对照组皮肤改善情况:
表2.DT001对皮肤的改善情况(DT001:高原儿茶酸负载香菇菌多糖复合物):
表3.甘草酸二钾对皮肤的改善情况(GK2:甘草酸二钾):
表4.红没药醇对皮肤的改善情况(Drag:红没药醇):
表5.氢化可的松对皮肤的改善情况(Hydr:氢化可的松):
结论:
DT001可有效改善皮肤的保水性能,提高皮层胶原蛋白含量,改善皮肤弹性。对保水性能的最高改善率优于红没药醇,与甘草酸二钾和氢化可的松效果相当;对胶原蛋白含量的改善优于三种阳性药;对皮肤弹性的最高改善率优于氢化可的松,与甘草酸二钾和红没药醇效果相当。与对照组比较,DT001对皮肤的改善效果优于甘草酸二钾、红没药醇和氢化可的松。
尽管已经示出和描述了本发明的实施例,对于本领域的普通技术人员而言,可以理解在不脱离本发明的原理和精神的情况下可以对这些实施例进行多种变化、修改、替换和变型,本发明的范围由所附权利要求及其等同物限定。
Claims (10)
2.根据权利要求1所述的高原儿茶酸负载香菇菌多糖复合物,其特征在于:所述复合物由如下重量百分比的原料合成,
香菇菌多糖,含量80-99%;
高原儿茶酸,含量1%-20%。
3.一种根据权利要求1所述的高原儿茶酸负载香菇菌多糖复合物的制备方法,其特征在于,采用生物发酵提取方法,具体包括以下步骤:
S1:称取1kg新鲜绿茶茶叶,同时加入40g蔗糖、6g蛋白胨、6g磷酸二氢钾等,然后按照茶叶与水重量比为1:1的比例使茶叶和水充分混匀;
S2:在121℃高温条件下充分灭菌20-30分钟后得到茶叶培养基;待培养基冷却至室温后,在超净工作台中将100克香菇菌丝体加入到1kg所述茶叶培养基中,于28℃、130rpm摇床里培养30d后,收集菌丝体和发酵液;
S3:对香菇菌丝体的发酵产物水提醇沉分离提取,得到复合物粗品;
S4:将粗品复溶于500ml去离子水中得到灰色溶液,用10KD的透析袋在去离子水中透析3次,每次透析8小时,将透析后的反应液进行冷冻干燥,得到13.2克的淡灰色粉末,为负载后的高原儿茶酸负载香菇菌多糖复合物。
4.根据权利要求1所述的高原儿茶酸负载香菇菌多糖复合物的制备方法,其特征在于,采用化学合成方法,具体包括以下步骤:
S1:首先,将高原儿茶酸与香菇菌多糖以相应的比例混合在去离子水中,即可称取10克高原儿茶酸(93.6mmol)与100克香菇菌多糖溶于500ml去离子水中,机械搅拌(800转/分钟)10分钟使得高原儿茶酸较好的分散于水溶液中,此时溶液为灰色乳浊液;
S2:随后加入19.3克DCC(二环己基碳二亚胺,93.6mmol)作为缩合剂,在室温25℃下继续搅拌24h,反应结束后,反应液体系变得较为透明,为淡灰色溶液,用10KD的透析袋在去离子水中透析3次,每次透析8小时,将透析出的水溶液进行浓缩提取,得到4.7克的高原儿茶酸,可以得知有5.3克的高原儿茶酸负载到香菇多糖中;
S3:将透析后的反应液进行冷冻干燥,得到105.3克的淡灰色粉末,为高原儿茶酸负载香菇菌多糖复合物。
5.根据权利要求3或5所述的制备方法,其特征在于,所述的两种制备方法分别获得的高原儿茶酸负载香菇菌多糖复合物为相同产物,干燥状态下均为淡灰色粉末。
6.根据权利要求1所述的高原儿茶酸负载香菇菌多糖复合物,其特征在于:主要以水性糊剂或凝胶或液体的形式,例如水性液体的形式。
7.一种高原儿茶酸负载香菇菌多糖复合物的应用,其特征在于:将高原儿茶酸负载香菇菌多糖复合物配制为含水洗液、油包水或水包油乳液、油或油.醇洗液、阴离子或非离子两亲脂质的囊状分散体、含水凝胶、水.醇凝胶、醇凝胶或油.醇凝胶、固体棒或气溶胶。
8.一种高原儿茶酸负载香菇菌多糖复合物的应用,其特征在于:将高原儿茶酸负载香菇菌多糖复合物用于抗炎、促成纤维细胞增殖、护肤的制剂。
9.根据权利要求8所述的应用,其特征在于:所述剂型为临床上可接受的任一剂型。
10.根据权利要求9所述的应用,其特征在于:所述高原儿茶酸负载香菇菌多糖复合物为所述抗炎、促成纤维细胞增殖或护肤的唯一活性成分,或该复合物与其他物质一起制备所述抗炎、促成纤维细胞增殖或护肤的制剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011241931.2A CN112316155A (zh) | 2020-11-09 | 2020-11-09 | 高原儿茶酸负载香菇菌多糖复合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011241931.2A CN112316155A (zh) | 2020-11-09 | 2020-11-09 | 高原儿茶酸负载香菇菌多糖复合物及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112316155A true CN112316155A (zh) | 2021-02-05 |
Family
ID=74316411
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011241931.2A Pending CN112316155A (zh) | 2020-11-09 | 2020-11-09 | 高原儿茶酸负载香菇菌多糖复合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112316155A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1336602A1 (en) * | 2002-02-13 | 2003-08-20 | Giovanni Scaramuzzino | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases |
CN110638829A (zh) * | 2019-03-01 | 2020-01-03 | 上海澄穆生物科技有限公司 | 一种高原儿茶酸负载香菇菌多糖复合物的制备方法及应用 |
-
2020
- 2020-11-09 CN CN202011241931.2A patent/CN112316155A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1336602A1 (en) * | 2002-02-13 | 2003-08-20 | Giovanni Scaramuzzino | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases |
CN110638829A (zh) * | 2019-03-01 | 2020-01-03 | 上海澄穆生物科技有限公司 | 一种高原儿茶酸负载香菇菌多糖复合物的制备方法及应用 |
Non-Patent Citations (1)
Title |
---|
网络: "至本实验室与南开大学共同研发的Polycalm®正式发布", 《HTTP://WWW.CHINAJICENG.COM.CN/WH/2020-04-10/173608.HTML,基层网》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chithra et al. | Influence of Aloe vera on the healing of dermal wounds in diabetic rats | |
EP1859834B1 (en) | Anti-inflammatory agent | |
WO2022183763A1 (zh) | 一种铁皮石斛寡糖、铁皮石斛寡糖衍生物及其制备方法和应用 | |
JP2023015294A (ja) | 皮膚化粧料、頭髪化粧料および飲食品 | |
CN104274355A (zh) | 含有草绿盐角草和芦根的复合提取物的化妆品组合物 | |
US20180325969A1 (en) | Cosmetic and pharmaceutical applications of lactobacillus pentosus | |
CN108703908B (zh) | 一种抗痘祛斑精华液及其制备方法 | |
KR20020011957A (ko) | 항-라디칼형 작용을 하는 식물 추출물의 용도 | |
CN117530911B (zh) | 一种雪莲花发酵产物及其制备方法、应用和化妆品 | |
CN110638829A (zh) | 一种高原儿茶酸负载香菇菌多糖复合物的制备方法及应用 | |
JP5060690B2 (ja) | サイクリックampホスホジエステラーゼ阻害剤 | |
CN112316155A (zh) | 高原儿茶酸负载香菇菌多糖复合物及其制备方法和应用 | |
CN110638688A (zh) | 一种青蒿素负载香菇菌多糖复合物的制备方法及应用 | |
CN110638687A (zh) | 一种丹参素负载香菇菌多糖复合物的制备方法及应用 | |
CN110638680A (zh) | 一种槲皮素负载香菇菌多糖复合物的制备方法及应用 | |
WO2020062453A1 (zh) | 一种酪氨酸酶抑制剂在面霜、洗面奶或美白乳液中的应用 | |
CN109674839A (zh) | 一种酪氨酸酶抑制剂及其制备方法和用途 | |
JP7215761B2 (ja) | 経口組成物、皮膚化粧料および頭髪化粧料 | |
CN117695176A (zh) | 发酵法制备银耳提取物的工艺及包含银耳提取物的组合物 | |
CN114652850B (zh) | 一种具有抗衰老作用的多肽偶联nmn化合物及其应用 | |
CN114907575B (zh) | 一种水溶性木质素及其制备方法和应用 | |
CN116655817B (zh) | 一种酶解耦合深共熔溶剂提取极微小球藻多糖的方法及应用 | |
TW201813652A (zh) | 江氏龍鬚菜水萃取物的水解產物及其製備方法與用途 | |
CN116422002B (zh) | 一种芦荟提取物及其制备方法与应用 | |
WO2017113263A1 (zh) | 木质醋酸菌发酵液作为化妆品组合物之新颖用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210205 |
|
RJ01 | Rejection of invention patent application after publication |